Trellus Health signs renewal of licensing deal with Pfizer

(Alliance News) - Trellus Health PLC on Monday said it signed a renewal of its licensing ...

Alliance News 13 April, 2026 | 10:28AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Trellus Health PLC on Monday said it signed a renewal of its licensing agreement with New York-based pharmaceutical company Pfizer Inc.

The London-based healthcare company said under the renewal, Pfizer will continue to license Trellus Health's patient support educational content for inclusion within its inflammatory bowel disease digital application. The contract was originally signed in the second quarter of 2024.

Trellus Health shares jumped 50% to 0.30 pence each on Monday morning in London. Pfizer shares were virtually flat at USD26.91 each in pre-market trading in New York.

Trellus Health Chief Executive Officer Marla Dubinsky said: "We are excited to extend this agreement with Pfizer, which underscores both the continued engagement of their users with our content on the platform and the value of our resilience-driven approach and methodology. Alongside our recent Gastro Health Master Services Agreement, the extension of our collaboration with Johnson & Johnson, and the continued roll-out of TrialSet across clinical trials, this renewal further supports the applicability of our platform across the pharmaceutical lifecycle. We remain focused on advancing commercial discussions and converting pipeline opportunities into revenue."

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Trellus Health PLC Ordinary Shares 0.55 -
Johnson & Johnson 201.62
Pfizer Inc 25.77

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures